Medulloblastoma Down under 2013

A report from the third annual meeting of the International Medulloblastoma Working Group

Nicholas G. Gottardo, Jordan R. Hansford, Jacqueline P. McGlade, Frank Alvaro, David M. Ashley, Simon Bailey, David L. Baker, Franck Bourdeaut, Yoon-Jae Cho, Moira Clay, Steven C. Clifford, Richard J. Cohn, Catherine H. Cole, Peter B. Dallas, Peter Downie, François Doz, David W. Ellison, Raelene Endersby, Paul G. Fisher, Timothy Hassall & 31 others John A. Heath, Hilary L. Hii, David T.W. Jones, Reimar Junckerstorff, Stewart Kellie, Marcel Kool, Rishi S. Kotecha, Peter Lichter, Stephen J. Laughton, Sharon Lee, Geoff McCowage, Paul A. Northcott, James M. Olson, Roger J. Packer, Stefan M. Pfister, Torsten Pietsch, Barry Pizer, Scott L. Pomeroy, Marc Remke, Giles W. Robinson, Stefan Rutkowski, Tobias Schoep, Anang A. Shelat, Clinton F. Stewart, Michael Sullivan, Michael D. Taylor, Brandon Wainwright, Thomas Walwyn, William A. Weiss, Dan Williamson, Amar Gajjar

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Medulloblastoma is curable in approximately 70 % of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.

Original languageEnglish (US)
Pages (from-to)189-201
Number of pages13
JournalActa Neuropathologica
Volume127
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Annual Reports
Medulloblastoma
Clinical Trials
Drug Delivery Systems
Therapeutics
Central Nervous System Neoplasms
Preclinical Drug Evaluations
Translational Medical Research
Hedgehogs
Molecular Pathology
Rare Diseases
Genomics
Survivors
Consensus
Joints
Quality of Life
Survival
Research

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Gottardo, N. G., Hansford, J. R., McGlade, J. P., Alvaro, F., Ashley, D. M., Bailey, S., ... Gajjar, A. (2014). Medulloblastoma Down under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189-201. https://doi.org/10.1007/s00401-013-1213-7

Medulloblastoma Down under 2013 : A report from the third annual meeting of the International Medulloblastoma Working Group. / Gottardo, Nicholas G.; Hansford, Jordan R.; McGlade, Jacqueline P.; Alvaro, Frank; Ashley, David M.; Bailey, Simon; Baker, David L.; Bourdeaut, Franck; Cho, Yoon-Jae; Clay, Moira; Clifford, Steven C.; Cohn, Richard J.; Cole, Catherine H.; Dallas, Peter B.; Downie, Peter; Doz, François; Ellison, David W.; Endersby, Raelene; Fisher, Paul G.; Hassall, Timothy; Heath, John A.; Hii, Hilary L.; Jones, David T.W.; Junckerstorff, Reimar; Kellie, Stewart; Kool, Marcel; Kotecha, Rishi S.; Lichter, Peter; Laughton, Stephen J.; Lee, Sharon; McCowage, Geoff; Northcott, Paul A.; Olson, James M.; Packer, Roger J.; Pfister, Stefan M.; Pietsch, Torsten; Pizer, Barry; Pomeroy, Scott L.; Remke, Marc; Robinson, Giles W.; Rutkowski, Stefan; Schoep, Tobias; Shelat, Anang A.; Stewart, Clinton F.; Sullivan, Michael; Taylor, Michael D.; Wainwright, Brandon; Walwyn, Thomas; Weiss, William A.; Williamson, Dan; Gajjar, Amar.

In: Acta Neuropathologica, Vol. 127, No. 2, 01.02.2014, p. 189-201.

Research output: Contribution to journalArticle

Gottardo, NG, Hansford, JR, McGlade, JP, Alvaro, F, Ashley, DM, Bailey, S, Baker, DL, Bourdeaut, F, Cho, Y-J, Clay, M, Clifford, SC, Cohn, RJ, Cole, CH, Dallas, PB, Downie, P, Doz, F, Ellison, DW, Endersby, R, Fisher, PG, Hassall, T, Heath, JA, Hii, HL, Jones, DTW, Junckerstorff, R, Kellie, S, Kool, M, Kotecha, RS, Lichter, P, Laughton, SJ, Lee, S, McCowage, G, Northcott, PA, Olson, JM, Packer, RJ, Pfister, SM, Pietsch, T, Pizer, B, Pomeroy, SL, Remke, M, Robinson, GW, Rutkowski, S, Schoep, T, Shelat, AA, Stewart, CF, Sullivan, M, Taylor, MD, Wainwright, B, Walwyn, T, Weiss, WA, Williamson, D & Gajjar, A 2014, 'Medulloblastoma Down under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group', Acta Neuropathologica, vol. 127, no. 2, pp. 189-201. https://doi.org/10.1007/s00401-013-1213-7
Gottardo, Nicholas G. ; Hansford, Jordan R. ; McGlade, Jacqueline P. ; Alvaro, Frank ; Ashley, David M. ; Bailey, Simon ; Baker, David L. ; Bourdeaut, Franck ; Cho, Yoon-Jae ; Clay, Moira ; Clifford, Steven C. ; Cohn, Richard J. ; Cole, Catherine H. ; Dallas, Peter B. ; Downie, Peter ; Doz, François ; Ellison, David W. ; Endersby, Raelene ; Fisher, Paul G. ; Hassall, Timothy ; Heath, John A. ; Hii, Hilary L. ; Jones, David T.W. ; Junckerstorff, Reimar ; Kellie, Stewart ; Kool, Marcel ; Kotecha, Rishi S. ; Lichter, Peter ; Laughton, Stephen J. ; Lee, Sharon ; McCowage, Geoff ; Northcott, Paul A. ; Olson, James M. ; Packer, Roger J. ; Pfister, Stefan M. ; Pietsch, Torsten ; Pizer, Barry ; Pomeroy, Scott L. ; Remke, Marc ; Robinson, Giles W. ; Rutkowski, Stefan ; Schoep, Tobias ; Shelat, Anang A. ; Stewart, Clinton F. ; Sullivan, Michael ; Taylor, Michael D. ; Wainwright, Brandon ; Walwyn, Thomas ; Weiss, William A. ; Williamson, Dan ; Gajjar, Amar. / Medulloblastoma Down under 2013 : A report from the third annual meeting of the International Medulloblastoma Working Group. In: Acta Neuropathologica. 2014 ; Vol. 127, No. 2. pp. 189-201.
@article{6f161036004a4224ad922a949ef517e6,
title = "Medulloblastoma Down under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group",
abstract = "Medulloblastoma is curable in approximately 70 {\%} of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.",
author = "Gottardo, {Nicholas G.} and Hansford, {Jordan R.} and McGlade, {Jacqueline P.} and Frank Alvaro and Ashley, {David M.} and Simon Bailey and Baker, {David L.} and Franck Bourdeaut and Yoon-Jae Cho and Moira Clay and Clifford, {Steven C.} and Cohn, {Richard J.} and Cole, {Catherine H.} and Dallas, {Peter B.} and Peter Downie and Fran{\cc}ois Doz and Ellison, {David W.} and Raelene Endersby and Fisher, {Paul G.} and Timothy Hassall and Heath, {John A.} and Hii, {Hilary L.} and Jones, {David T.W.} and Reimar Junckerstorff and Stewart Kellie and Marcel Kool and Kotecha, {Rishi S.} and Peter Lichter and Laughton, {Stephen J.} and Sharon Lee and Geoff McCowage and Northcott, {Paul A.} and Olson, {James M.} and Packer, {Roger J.} and Pfister, {Stefan M.} and Torsten Pietsch and Barry Pizer and Pomeroy, {Scott L.} and Marc Remke and Robinson, {Giles W.} and Stefan Rutkowski and Tobias Schoep and Shelat, {Anang A.} and Stewart, {Clinton F.} and Michael Sullivan and Taylor, {Michael D.} and Brandon Wainwright and Thomas Walwyn and Weiss, {William A.} and Dan Williamson and Amar Gajjar",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/s00401-013-1213-7",
language = "English (US)",
volume = "127",
pages = "189--201",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Medulloblastoma Down under 2013

T2 - A report from the third annual meeting of the International Medulloblastoma Working Group

AU - Gottardo, Nicholas G.

AU - Hansford, Jordan R.

AU - McGlade, Jacqueline P.

AU - Alvaro, Frank

AU - Ashley, David M.

AU - Bailey, Simon

AU - Baker, David L.

AU - Bourdeaut, Franck

AU - Cho, Yoon-Jae

AU - Clay, Moira

AU - Clifford, Steven C.

AU - Cohn, Richard J.

AU - Cole, Catherine H.

AU - Dallas, Peter B.

AU - Downie, Peter

AU - Doz, François

AU - Ellison, David W.

AU - Endersby, Raelene

AU - Fisher, Paul G.

AU - Hassall, Timothy

AU - Heath, John A.

AU - Hii, Hilary L.

AU - Jones, David T.W.

AU - Junckerstorff, Reimar

AU - Kellie, Stewart

AU - Kool, Marcel

AU - Kotecha, Rishi S.

AU - Lichter, Peter

AU - Laughton, Stephen J.

AU - Lee, Sharon

AU - McCowage, Geoff

AU - Northcott, Paul A.

AU - Olson, James M.

AU - Packer, Roger J.

AU - Pfister, Stefan M.

AU - Pietsch, Torsten

AU - Pizer, Barry

AU - Pomeroy, Scott L.

AU - Remke, Marc

AU - Robinson, Giles W.

AU - Rutkowski, Stefan

AU - Schoep, Tobias

AU - Shelat, Anang A.

AU - Stewart, Clinton F.

AU - Sullivan, Michael

AU - Taylor, Michael D.

AU - Wainwright, Brandon

AU - Walwyn, Thomas

AU - Weiss, William A.

AU - Williamson, Dan

AU - Gajjar, Amar

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Medulloblastoma is curable in approximately 70 % of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.

AB - Medulloblastoma is curable in approximately 70 % of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84896692613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896692613&partnerID=8YFLogxK

U2 - 10.1007/s00401-013-1213-7

DO - 10.1007/s00401-013-1213-7

M3 - Article

VL - 127

SP - 189

EP - 201

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 2

ER -